Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Single-dose CAR-T approach wipes out lymphoma tumors in mice

☕ Includes a question for the family ↓

LymphomaPart of a story we are following · 3 articles · See every update
Bunches of fresh purple sprouting broccoli piled at a market stall.
Bunches of fresh purple sprouting broccoli piled at a market stall.Photo: Daderot / Wikimedia Commons, CC0

Here is some hopeful news from the lab. Scientists built a new way to make CAR-T cells inside the body with one injection, and in mice it cleared lymphoma tumors completely. This has not been tested in people yet.

In a study of mice carrying human lymphoma tumors, a single intravenous dose of a new gene-delivery virus called AVO-100 led to complete tumor eradication and longer survival, while untreated mice succumbed to progressive disease. The researchers describe it as a promising off-the-shelf approach for treating B cell cancers.

How the study worked

This was a preclinical study, which means it was done in lab-grown cells and in mice, not in people. The team first tested their method on human T cells in the lab, then in mice bearing tumors made from human lymphoma cells. It was published in Molecular Therapy on November 6, 2026. Results in mice do not always carry over to people, so the next step is testing in human patients.

What is CAR-T therapy, in plain words?

T cells are immune cells that patrol your body. CAR-T therapy gives T cells a new feature, called a chimeric antigen receptor (CAR), that lets them find and attack a specific target on cancer cells. In this study, the target was a marker called CD19, which sits on the surface of the lymphoma cells.

To add that feature, scientists need a delivery vehicle for the instructions. Here they used an adeno-associated virus, or AAV. Think of it as a tiny delivery van that carries a genetic message into a cell.

There was a catch. Natural AAV vans were considered a poor fit because they barely got into resting human T cells. This team solved that by attaching a small piece to the outside of the van. That piece, called CD3scFv, lets the van find T cells and wake them up.

What they found

The redesigned virus carried its load far better. The lead version, AVO-100, got into human T cells more than 200 times as efficiently as the unmodified virus. The exact figure in the study is more than 200-fold higher transduction efficiency. The change also did not hurt how much virus could be made, which matters for any treatment that would need to be produced at scale.

In the lab dish, T cells that received the CD19 instructions made the CAR and killed CD19-positive Raji lymphoma cells.

Then came the mouse test. Mice bearing Raji lymphoma tumors got a single intravenous dose of AVO-100, at 2×10^8 vector genomes per animal. The tumors were completely eradicated, and the mice lived significantly longer. The untreated mice did not do well. Their disease kept progressing.

The authors say the approach gives T cells their cancer-finding feature right in the body. That is why they call it off-the-shelf: one ready-made product instead of a treatment built one patient at a time.

What you can do today

There is nothing to do yet, because this treatment is not available to patients. Current lymphoma care and advice do not change because of this study. What it gives you is a reason for hope: a single-dose, ready-made CAR-T approach worked very well in mice, and it now moves toward the testing that will show whether it works in people.

For clinicians and researchers

Design: Preclinical study of an AAV6 capsid engineered with an anti-CD3 single-chain variable fragment (AVO-100), tested in primary human T cells, in CD19+ Raji lymphoma co-cultures and in NSG mice bearing Raji xenografts, versus unmodified AAV6 and untreated controls.

Main result: AVO-100 achieved more than 200-fold higher transduction efficiency of primary human T cells than unmodified AAV6. A single intravenous dose of 2×108 vector genomes per subject led to complete tumor eradication and significantly prolonged survival in mice.

Main limitation: Evidence comes from in vitro assays and an immunodeficient mouse xenograft model of a single lymphoma cell line, which limits extrapolation to human patients; no safety or human data are reported in the abstract.

How it fits: Extends earlier Mongevity coverage of CAR-T therapy for lymphoma by testing a different strategy: generating CAR-T cells in vivo rather than improving the T cells used in manufactured products. Younger T cells help CAR-T therapy for lymphoma last longer

Open question: Whether in vivo CAR-T generation with AVO-100 is safe and effective beyond xenograft models, including in other B cell malignancies and in humans, remains to be tested.

Talk about it at home

Your body has immune cells called T cells that patrol like security guards, but they need the right instructions to spot a particular troublemaker. In this study, scientists used a tiny harmless virus like a delivery van to carry those instructions into T cells, and they added a special key on the outside of the van so it could get through the door of the cell. In mice this worked very well, and the next step is careful testing to learn whether it also works in people.

Try it at home

Play delivery van at home: draw a simple shape on a piece of paper and tape it on a door, then give a family member a folded message with the same shape drawn on it. They have to find the matching door before they can deliver the message. Then swap roles and make the shapes trickier.

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Single-dose CAR-T approach wipes out lymphoma tumors in mice. Mongevity. Published November 22, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/single-dose-car-t-lymphoma-mice/
Vancouver
Mongevity Desk. Single-dose CAR-T approach wipes out lymphoma tumors in mice [Internet]. Mongevity; 2026 Nov 22 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/single-dose-car-t-lymphoma-mice/
APA
Mongevity Desk. (2026, November 22). Single-dose CAR-T approach wipes out lymphoma tumors in mice. Mongevity. https://mongevity.science/cancer/2026/11/single-dose-car-t-lymphoma-mice/
For your website
<a href="https://mongevity.science/cancer/2026/11/single-dose-car-t-lymphoma-mice/">Single-dose CAR-T approach wipes out lymphoma tumors in mice</a>

Free to share or quote with credit and a link.

Questions and answers

Can people get this lymphoma treatment now?
No. It was tested only in lab-grown cells and in mice. It has not been tested in people yet.
What does off-the-shelf CAR-T mean?
It means a ready-made product that makes the CAR-T cells inside the body, instead of a treatment built separately for each patient. The study calls this a promising off-the-shelf approach.
What happened to the mice in the study?
After a single intravenous dose, the lymphoma tumors were completely eradicated and the mice lived significantly longer. Untreated mice got worse as their disease progressed.
Why does the virus have a T cell tag on it?
Natural AAV viruses barely got into resting human T cells. Adding a piece called CD3scFv lets the virus find T cells and wake them up, which raised delivery by more than 200-fold.

Sources

  1. Mol Ther: CD3scFv-Engineered AAV Capsid Drives Superior In Vitro and In Vivo CAR-T Cell Generation and Leads to Complete Eradication of CD19+ Tumors (PMID 42995488 · DOI 10.1016/j.ymthe.2026.10.035) · 2026-11-22

More on this story

Report an error